Two brand-name versions of the most widely prescribed medicine in the country will go generic soon, signaling a major potential cost savings for consumers and the health-care industry that could total in the billions of dollars each year.
The cholesterol-lower statin Pravachol (pravastatin) is scheduled to go generic sometime this month, and Zocor (simvastatin) is slated to follow in June. Statin drugs to treat high cholesterol are among the most widely prescribed drugs in the United States, and Zocor is the No. 2 best-selling drug in the nation.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment